Nuwellis, Inc. (NUWE) - Q1 2026 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended March 31, 2026. Nuwellis, Inc. is a commercial-stage medical device company focused on precision cardiorenal care, primarily through its Aquadex SmartFlow® system for ultrafiltration therapy. The company operates as a single reporting segment. In March 2026, the company completed the asset acquisition of Rendiatech, Inc., adding automated kidney function monitoring technology to its platform. The company has exited substantially all international operations to focus on the U.S. market.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Net Sales | $2.40 million | $1.90 million |
| Gross Profit | $1.68 million | $1.07 million |
| Gross Margin | 70.1% | 56.0% |
| Operating Loss | $(4.57) million | $(3.06) million |
| Net Loss | $(4.54) million | $(3.01) million |
| Net Loss Per Share (Basic/Diluted) | $(2.19) | $(28.93) |
| Cash and Cash Equivalents (End of Period) | $2.08 million | $2.56 million |
| Net Cash Used in Operating Activities | $(3.11) million | $(2.54) million |
| Accumulated Deficit | $(320.85) million | $(301.81) million |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 26.2% year-over-year, driven by a 633% increase in console sales and a 15% increase in circuits.
- Margin Expansion: Gross margin improved to 70.1% from 56.0%, attributed to switching to contract manufacturing (KDI Precision Manufacturing).
- Expense Increases:
- SG&A: Increased 26.5% due to higher headcount, sales compensation, and professional fees.
- R&D: Increased 214.4% primarily due to the immediate expensing of $0.76 million in acquired in-process R&D from the Rendiatech acquisition, plus increased headcount and consulting fees.
- Capital Structure: Completed a private placement and warrant inducement in January 2026 raising approximately $5.0 million in gross proceeds. Issued 150,000 shares of common stock as partial consideration for the Rendiatech acquisition.
Outlook, Risks, and Contingencies
- Going Concern: The filing explicitly states that conditions raise substantial doubt about the company's ability to continue as a going concern for at least twelve months. Management believes existing capital resources will support operations only through the second quarter of 2026. Additional capital will be required to fund operations through the end of fiscal year 2026.
- Internal Controls: Management concluded that disclosure controls and procedures were not effective as of March 31, 2026, due to two material weaknesses in controls over financial reporting identified in the prior year.
- Legal Proceedings: Settled a lawsuit with E.F. Hutton & Co. for $204,000 in April 2026 (accrued as of March 31, 2026).
- Acquisition Integration: Risks related to the integration of Rendiatech technology and the potential earnout royalty (9% of gross sales, capped at $2 million) are noted.
Investor Verification Checklist
- Cash Runway: Verify the timeline for the next capital raise, as the company expects to exhaust resources by Q2 2026.
- Revenue Concentration: Note that three customers represented 35% of Q1 2026 net sales (14%, 11%, and 10%).
- Warrant Liability: Review the fair value changes of warrant liabilities ($362k at period end) and the significant number of warrants outstanding (~4.8 million shares underlying).
- Internal Control Remediation: Monitor progress on remediation of the two material weaknesses in financial reporting controls.
- Rendiatech Integration: Assess the commercial viability and regulatory timeline for the acquired kidney monitoring technology to determine if it will generate future revenue.